[Ru(phen)2(3,8-2R-phen)]2+(R=OH,H,F)电子结构与抗癌活性研究

用密度泛函(DFT)法,对配合物[Ru(phen)2(3,8-2R-phen)]2+(R=OH,H,F)进行了理论计算研究.探讨了配合物的电子结构与其抗癌活性的关系:主配体上3,8位上F原子的取代有利于配合物与DNA的作用,增加配合物的抗癌活性.计算结果能较好地预测配合物与DNA的作用强度、抗癌活性及指导具有较高抗癌活性配合物的合成.     

N-[5-（3-吡啶基）-1，3，4-噻二唑-2-基]-N＇-芳甲酰基脲的合成及抗菌活性

1，3，4-噻二唑衍生物具有抗真菌、抗菌、抗惊厥和抗结核等广泛的生物活性。因而该类化合物的研究迄今仍方兴未艾。从生物化学的角度来看，吡啶环中的N原子可参与生物体中氢键的形成。可以增加药物与受体间的亲和力和选择性。故吡啶环的引入有望提高化合物的生物活性；且在新药设计中吡啶作为苯环的生物电子等排体常被用作药效团。吡啶衍生物已成为近些年来新药设计与开发的热点领域之一。而取代脲类化合物具有抗癌。等生理活性也倍受关注。     

2，3-二氢喹啉-4（1H）-酮缩氨基脲类化合物的设计、合成及抗真菌活性研究

目的合成一系列二氯-2,3-二氢喹啉4（1H）-酮缩氨基脲类化合物并测定其体外抗真菌活性。方法以二氯苯胺和丙烯酸为起始原料,经加成、环合制得中间体5,7-二氯-2,3-二氢喹啉-4（1H）-酮和6,8-二氯-2,3-二氨喹啉-4（1H）-酮;中间体与各种胪-取代的氨基脲缩合得到目标化合物;采用二倍浓度稀释法测试各目标化合物的体外抗真菌活性,实验选用9种临床上常见的致病真菌为测试菌株,以氟康唑为阳性对照药。结果与结论合成的24个化合物均未见文献报道,其结构经。H-NMR、Ms谱确证;活性测试结果表明,多个目标化合物对测试真菌表现出较好的体外抑菌活性。     

1,4-二氢噻吩并[3',2':5,6]噻喃并[4,3-c]吡唑-3-羧酸衍生物的合成及抗癌活性研究(英文)

本文以2-巯基噻吩为原料,经6步反应合成了5个1,4-二氢噻吩并[3',2':5,6]噻喃并[4,3-c]吡唑-3-羧酸衍生物,并采用人乳腺癌细胞MCF-7对目标化合物的抗肿瘤活性进行初步评价。所合成化合物在100μM浓度下均有一定的抑制MCF-7活性。     

具有抗肿瘤活性的6,7-二氰基-二吡啶基[2,2-d:2′,3′-f]喹喔啉合钴 (II)配合物的合成、晶体结构及与DNA结合的研究(英文)

合成了 6 ,7 二氰基 二吡啶 [2 ,2 d :2′ ,3′ f]喹喔啉 (L)与钴 (II)形成的配合物 [CoL(NO3 ) 2 (CH3 CN) ](1)。通过元素分析、IR对其组成和性质进行了表征 ,并测定了它的晶体结构。结果表明 ,钴原子与 3个N原子和四个O氧原子形成变形五角双锥配位构型。体外抗肿瘤活性筛选试验结果表明 :该配合物具有强的抗肿瘤活性 ,且配合物活性明显优于配体。通过紫外滴定、粘度滴定、解链温度测定等方法研究了化合物及配体与CT DNA的作用模式及结合常数 ,结果表明配合物与CT DNA的作用模式为典型的嵌插作用 ,配合物和配体与CT DNA的结合常数分别为 4 .4 3× 10 5mol·L-1和 1.6 5× 10 5mol·L-1。     

具有抗肿瘤活性的6,7-二氰基-二吡啶基[2,2-d:2',3'-f]喹喔啉合钴(Ⅱ)配合物的合成、晶体结构及与DNA结合的研究

合成了6,7-二氰基-二吡啶[2,2-d:2′,3′-f]喹喔啉(L)与钴(Ⅱ)形成的配合物[CoL(NO3)2(CH3CN)](1).通过元素分析、IR对其组成和性质进行了表征,并测定了它的晶体结构.结果表明,钴原子与3个N原子和四个O氧原子形成变形五角双锥配位构型.体外抗肿瘤活性筛选试验结果表明:该配合物具有强的抗肿瘤活性,且配合物活性明显优于配体.通过紫外滴定、粘度滴定、解链温度测定等方法研究了化合物及配体与CT-DNA的作用模式及结合常数,结果表明配合物与CT-DNA的作用模式为典型的嵌插作用,配合物和配体与CT-DNA的结合常数分别为4.43×105mol·L-1和1.65×105mol·L-1.     

5’（S）-1，1-亚乙二氧基-5-氧代-（5’-乙基-5’-羟基-2’H,5’H，6＇H-6-氧代吡喃）-[3’-4’-f]-△^6（8）-四氢中氮茚的合成研究

目的合成20（S）-喜树碱类抗肿瘤药物关键中间体5’（S）-1，1-亚乙二氧基-5-氧代-（5’-乙基-5，-羟基-2’H，5＇H，6＇H-6-氧代吡喃）-[3’，4＇-f]-△^6（8）-四氢中氮茚。方法以1，1-亚乙二氧基-5-氧代-（5’-乙基-2’H，5＇H，6＇H-6-氧代吡喃）-[3’，4＂-f]-△^6（8）-四氢中氮茚为原料，经碘催化氧化、动力学拆分、碱水解3步得到光学纯目标化合物。结果与结论该合成路线操作简单，总收率15．7％，ee值96％。     

［Ln(Phen)2(5-Fu)3(NO3)］(NO3)2的合成、表征及体外抗肿瘤活性研究

目的研究稀土元素的生物化学作用和无机、有机抗肿瘤药物的协同作用。方法用稀土硝酸盐、邻菲罗啉(Phen)、氟尿嘧啶(5-Fu)合成了7种稀土配合物。用MTT,SRB法进行体外抗肿瘤活性研究。结果经过元素分析、摩尔电导率测定、差热分析、红外光谱测定和核磁共振谱测定，初步确定配合物化学式为［Ln(Phen)₂(5-Fu)₃(NO₃)］(NO₃)₂。配合物对K562(人粒细胞白血病细胞株)、CA(人肝癌细胞株)、SGC-7901(人胃癌细胞株)、HCT(人结肠癌细胞株)、GLC-82(人肺癌细胞株)和CNE(人鼻咽癌细胞株)增殖有很强的抑制作用。结论配合物产生了抗肿瘤协同作用。     

Studies on the interactions between DNA and PAMAM with fluorescent probe [Ru(phen)2 dppz]2+

The interactions between plasmid DNA and cationic polymers are of interest for their potential biological applications. In this paper, the interactions of DNA with polyamidoamine (PAMAM) dendrimer were studied by fluorescence spectroscopy and stopped-flow technique. A rapid and reproducible fluorescent assay method had been developed for assessing PAMAM and DNA interactions using [Ru(phen)2 dppz]2+ as a probe. We further studied the kinetics of PAMAM binding to DNA and the reverse process of DNA dissociation from the complexes. The results indicated that DNA condensation was the rate-determining step during the complexation process, while DNA unfolding and expansion was the rate-determining step during the DNA dissociation process. At N/P ratios before reaching the thermodynamically most stable state, the complexes of DNA and PAMAM were incompact and could dissociate to some extent. And at N/P ratios above 2.0, DNA was fully condensed by PAMAM and dissociation was increasingly difficult. These results provided some useful instructions for self-assembling and disassembling of DNA as well as efficient gene delivery applications.     

Enantioselective synthesis of (R)- and (S)-2-methyl-[3,3,2-2H3] alanines

The synthesis of optically pure (R)- and (S)-2-methyl-[3,3,3-²H₃] alanines of biological interest is described. The stereochemistry of the reaction of the lithio derivative of (R)-(©)-2,5-dimethoxy-3-benzyl-3-methyl-3, 6-dihydropyrazine with alkyl and deuterated alkyl iodides is discussed. The configuration of the newly formed center of chirality in (R)- and (S)-2-methyl-[3,3,3-²H₃] alanines is derived from ¹ H NMR.     

(R)-3-氨基-2,3,4,5-四氢-1H-[1]-2-氧代苯并氮杂(艹卓)的合成

3,4-二氢-2H-萘-1-酮与盐酸羟胺反应后,在PPA中经Beckmann重排、碘代得到3-碘代-2,3,4,5-四氢-1H-[1]-2-氧代苯并氮杂(5),5经氨解、D-焦谷氨酸拆分、浓氨水处理后催化氢化还原,得到(R)-3-氨基-2,3,4,5-四氢-1H[1]-2-氧代苯并氮杂(艹卓),总收率约44%,纯度98%,ee值99.5%.     

Studies of metabolic fate of a new antiallergic agent, azelastine (4-(p-chlorobenzyl)-2-[N-methylperhydroazepinyl-(4)]-1-(2H)-phthalazinone hydrochloride)

The metabolic fate of a new antiallergic agent, azelastine (4-(p-chlorobenzyl)-2-[N-methylperhydroazepinyl-(4)]-1-(2H)-phthalazinone hydrochloride) in rats and guinea pigs was investigated using its 14C-labelled compound. The blood level of radioactivity reached the maximum at 1-1.5 hr after oral administration, indicating the rapid absorption of the drug from gastrointestinal tract. A high concentration of radioactivity was detected in the lung of both species following either oral or intravenous administration. The major pathway of excretion of radioactivity was by way into feces, in both species. The radioactivity excreted in feces was attributable to that which was excreted in bile and exsorbed into gastrointegtinal tract. When the drug was given to pregnant rats, the concentration of radioactivity in the fetus was significantly lower than those in placenta and uterus, indicating the limited placental transfer of the drug. The successive oral administration of the drug in lower doses exerted no effect on the activity of microsomal drug-metabolizing enzymes of rat liver, while in higher doses, had a slight effect.     

Comparison of the relative effects of 1,24-dihydroxyvitamin D(2) [1, 24-(OH)(2)D(2)], 1,24-dihydroxyvitamin D(3) [1,24-(OH)(2)D(3)], and 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] on selected vitamin D-regulated events in the rat

The present experiments were conducted to compare the relative hypercalciuric and hypercalcemic activities of 1,24-dihydroxyvitamin D(2) [1,24-(OH)(2)D(2)], 1,24-dihydroxyvitamin D(3) [1, 24-(OH)(2)D(3)], and 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] in 7-week-old rats. The rats were dosed orally with each sterol for 7 days at a rate of 1 ng/g body weight/day. We also monitored the effect of the three compounds on the induction of mRNA for CaATPase and for 25-hydroxyvitamin D-24-hydroxylase in the kidney and intestine, on plasma vitamin D metabolite levels, and on the capacity to evoke modification in the vitamin D receptor/retinoic acid X receptor (VDR/RXR) heterodimer conformation. Plasma calcium was elevated in the rats treated with 1,24-(OH)(2)D(3) and 1, 25-(OH)(2)D(3), but not in the 1,24-(OH)(2)D(2)-dosed rats. Urinary calcium was elevated significantly (relative to controls) in all groups. The order of hypercalciuric activity was 1,25-(OH)(2)D(3) >/= 1,24-(OH)(2)D(3) >/= 1,24-(OH)(2)D(2) > control. Duodenal plasma membrane calcium ATPase (PMCA) mRNA was elevated to a similar extent in all groups relative to controls. Duodenal 24-hydroxylase mRNA was elevated in all groups relative to controls; however, the elevations were significantly higher in the 1,24-(OH)(2)D(3) and 1, 25-(OH)(2)D(3) groups compared with the 1,24-(OH)(2)D(2) group. Kidney 24-hydroxylase also was elevated significantly in the 1, 24-(OH)(2)D(3)- and 1,25-(OH)(2)D(3)-treated rats but not in the 1, 24-(OH)(2)D(2)-treated rats. Recombinant human vitamin D receptor (hVDR) extracts were incubated with saturating concentrations of 1, 24-(OH)(2)D(2), 1,24-(OH)(2)D(3), and 1,25-(OH)(2)D(3) and subsequently analyzed by electrophoretic mobility shift assay (EMSA). Overall binding was comparable for all metabolites; however, the 1, 24-(OH)(2)D(2) complex exhibited distinctly altered mobility relative to 1,24-(OH)(2)D(3) and 1,25-(OH)(2)D(3), suggestive of an effect on hVDR/hRXR conformation. These data suggest that 1, 24-(OH)(2)D(2) is not as potent as either of the vitamin D(3) sterols at affecting hypercalcemia or hypercalciuria in young growing rats; however, 1,24-(OH)(2)D(2) can evoke other biological responses similar to the vitamin D(3) sterols. These different responses may be related to the alterations in conformation state of the hVDR/hRXR heterodimer.     

Effects of a novel glutamate transporter blocker, (2S, 3S)-3-[3-[4-(trifluoromethyl)benzoylamino]benzyloxy]aspartate (TFB-TBOA), on activities of hippocampal neurons

Glutamate transporters rapidly take up synaptically released glutamate and maintain the glutamate concentration in the synaptic cleft at a low level. (2S, 3S)-3-[3-[4-(trifluoromethyl)benzoylamino]benzyloxy]aspartate (TFB-TBOA) is a novel glutamate transporter blocker that potently suppresses the activity of glial transporters. TFB-TBOA inhibited synaptically activated transporter currents (STCs) in astrocytes in the stratum radiatum in rat hippocampal slices in a dose-dependent manner with an IC50 of 13 nM, and reduced them to approximately 10% of the control at 100 nM. We investigated the effects of TFB-TBOA on glutamatergic synaptic transmission and cell excitability in CA1 pyramidal cells. TFB-TBOA (100 nM) prolonged the decay of N-methyl-D-aspartic acid receptor (NMDAR)-mediated excitatory postsynaptic currents (EPSCs), whereas it prolonged that of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-mediated EPSCs only when the desensitization of AMPARs was reduced by cyclothiazide (CTZ). Furthermore, long-term application of TFB-TBOA induced spontaneous epileptiform discharges with a continuous depolarization shift of membrane potential. These epileptiform activities were mainly attributed to NMDAR activation. Even after pharmacological block of NMDARs, however, TFB-TBOA induced similar changes by activating AMPARs in the presence of CTZ. Thus, the continuous uptake of synaptically released glutamate by glial transporters is indispensable for protecting hippocampal neurons from glutamate receptor-mediated hyperexcitabilities.     

1,3-二甲基-6-[2-(对甲苯磺酰氧基)乙基氨基]尿嘧啶的合成

目的:合成盐酸尼非卡兰中间体1,3-二甲基-6-[2-(对甲苯磺酰氧基)乙基氨基]尿嘧啶.方法:以二甲基脲和氰乙酸为原料经3步反应合成目标产物.结果:以氰乙酸计,总收率44.4%.目标产物的光谱数据与文献报道一致.结论:新的合成方法所用原料价廉易得,适合生产.     

液相色谱-串联质谱法分析抗肿瘤新药乙烷硒啉在大鼠体内的代谢产物

本研究对抗肿瘤新药1,2-[二(1,2-苯并异硒唑-3(2H)-酮)]乙烷(乙烷硒啉,BBSKE)在大鼠体内的代谢产物进行鉴定。在灌胃给予大鼠单剂量乙烷硒啉200mg·kg-1后,采用液相色谱-串联质谱法(LC-MSn)对大鼠尿液、粪样、胆汁和血浆中的代谢产物进行检测,通过全扫描和选择离子扫描,以及根据多级质谱裂解规律对代谢物的结构进行分析。研究发现在大鼠尿样、粪样、胆汁和血浆中检测到3种Ⅰ相代谢产物和1种Ⅱ相代谢产物,其代谢途径分别为氧化、甲基化、硫甲基化和葡萄糖醛酸化反应,提示乙烷硒啉在大鼠体内的代谢方式可能是通过氧化、甲基化及葡萄糖醛酸化反应形成代谢产物。